Clinical Trial Update: Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, and immunogenicity of a cytomegalovirus DNA vaccine for congenital CMV infection; the study has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Cytomegalovirus Infection

Drugs mentioned

• Cytomegalovirus DNA vaccine (cytomegalovirus DNA vaccine)

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Congenital Cytomegalovirus Infection | Phase 1 | Status: WITHDRAWN